Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

Abstract Background The RAF–MEK–ERK pathway is commonly activated in pancreatic cancer because of a high frequency of KRAS-BRAF mutations. A phase II randomized trial was designed to investigate the activity of sorafenib in combination with chemotherapy in advanced pancreatic cancer. Methods Locally...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2014-02, Vol.46 (2), p.182-186
Hauptverfasser:	Cascinu, Stefano, Berardi, Rossana, Sobrero, Alberto, Bidoli, Paolo, Labianca, Roberto, Siena, Salvatore, Ferrari, Daris, Barni, Sandro, Aitini, Enrico, Zagonel, Vittorina, Caprioni, Francesco, Villa, Federica, Mosconi, Stefania, Faloppi, Luca, Tonini, Giuseppe, Boni, Corrado, Conte, Pierfranco, Di Costanzo, Francesco, Cinquini, Michela
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Female Gastroenterology and Hepatology Gemcitabine Humans Male Middle Aged Niacinamide - administration & dosage Niacinamide - analogs & derivatives Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Phase II study Phenylurea Compounds - administration & dosage Sorafenib Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!